COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review  

作　　者：Valentina Bonuomo Isacco Ferrarini Michele Dell'Eva Eugenio Sbisà Mauro Krampera Carlo Visco 

机构地区：[1]Section of Haematology,Department of Medicine,University of Verona,Verona 37134,Italy

出　　处：《World Journal of Virology》2021年第6期312-325,共14页世界病毒学杂志

摘　　要：Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection now has a global resonance and represents a major threat for several patient populations.Observations from initial case series suggested that cancer patients in general might have an unfavorable outcome following coronavirus disease 2019(COVID-19),due to their underlying conditions and cytotoxic treatments.More recently,data regarding the incidence and clinical evolution of COVID-19 in lymphomas have been reported with the aim to identify those more frequently associated with severe complications and death.Patients with lymphoma appear particularly vulnerable to SARS-CoV-2 infection,only partly because of the detrimental effects of the anti-neoplastic regimens(chemotherapy,pathway inhibitors,monoclonal antibodies)on the immune system.Here,we systematically reviewed the current literature on COVID-19 in adult patients with lymphoma,with particular emphasis on disease course and prognostic factors.We also highlighted the potential differences in COVID-19 clinical picture according to lymphoma subtype,delivered treatment for the hematological disease and its relationship on how these patients have been managed thus far.

关 键 词：LYMPHOMA SARS-CoV-2 infection Hematological malignancies COVID-19 RITUXIMAB BENDAMUSTINE 

分 类 号：R73[医药卫生—肿瘤]